Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financial targets.</li></ul>

Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financial targets.

<ul><li>Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.</li></ul>

Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.

Oncopeptides: Key Takeaways from the Capital Markets Update

<ul><li>Redeye comments on Oncopeptides’ 3rd quarter report.</li><li>Sales grew 5% versus Q2 2025.</li><li>Operating costs amounted to SEK-67m, with an EBIT of SEK-47m.</li></ul>

Redeye comments on Oncopeptides’ 3rd quarter report.Sales grew 5% versus Q2 2025.Operating costs amounted to SEK-67m, with an EBIT of SEK-47m.

Oncopeptides (Q3 Update): Q/Q Growth Only 5%, but 2026 Looks Promising

<ul><li>Redeye provides its first take on Oncopeptides' Q3 report 2025.</li><li>Sales grew 5% versus Q2 2025.</li><li>Operating costs amounted to SEK-67m, with an EBIT of SEK-47m.</li></ul>

Redeye provides its first take on Oncopeptides' Q3 report 2025.Sales grew 5% versus Q2 2025.Operating costs amounted to SEK-67m, with an EBIT of SEK-47m.

Oncopeptides (Q3 Initial take): Sequential Growth of 5%

<ul><li>Redeye is not surprised by the high subscription rate, considering the share has traded above the strike price.</li><li>The amount received should cover the company until reaching a positive cash flow.</li></ul>

Redeye is not surprised by the high subscription rate, considering the share has traded above the strike price.The amount received should cover the company until reaching a positive cash flow.

Sweden

Oncopeptides AB is a biotech company that engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases. The company's lead product is Pepaxti (melflufen), a peptide-drug conjugate for the treatment of relapsed or refractory multiple myeloma. Oncopeptides' proprietary Peptide Drug Conjugate (PDC) platform is designed to rapidly and selectively deliver cytotoxic agents into cancer cells.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oncopeptides (ONCO SS)

Oncopeptides: Q4 Sales Below Target

Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financial targets.

Redeye

Oncopeptides: Key Takeaways from the Capital Markets Update

Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.

Redeye

Oncopeptides (Q3 Update): Q/Q Growth Only 5%, but 2026 Looks Promising

Redeye comments on Oncopeptides’ 3rd quarter report. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m.

Redeye

Oncopeptides (Q3 Initial take): Sequential Growth of 5%

Redeye provides its first take on Oncopeptides' Q3 report 2025. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT...

Redeye

Oncopeptides: 157% subscription rate

Redeye is not surprised by the high subscription rate, considering the share has traded above the strike price. The amount received should cover...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)